130 related articles for article (PubMed ID: 38233246)
1. Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS).
Shi A; Nguyen H; Kuo CB; Beringer PM
J Cyst Fibros; 2024 May; 23(3):566-572. PubMed ID: 38233246
[TBL] [Abstract][Full Text] [Related]
2. Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study.
van der Meer R; Wilms EB; Eggermont MN; Paalvast HM; van Luin M; van Rossen RCJM; Heijerman HGM
J Cyst Fibros; 2024 May; 23(3):549-553. PubMed ID: 38290918
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review.
Testa I; Indolfi G; Brugha R; Verkade HJ; Terlizzi V
J Cyst Fibros; 2024 May; 23(3):554-560. PubMed ID: 38614868
[TBL] [Abstract][Full Text] [Related]
4. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
5. Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.
McKinzie CJ; Kam CW; Jones MC; Gifford LB; Loughlin CE; Noah TL; Shenoy VK; Dellon EP
Pediatr Pulmonol; 2024 Jun; 59(6):1795-1797. PubMed ID: 38517044
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
7. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
8. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
9. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
10. A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk.
Stylemans D; François S; Vincken S; Verbanck S; Vanderhelst E
J Cyst Fibros; 2021 Jul; 20(4):712-714. PubMed ID: 34134936
[No Abstract] [Full Text] [Related]
11. Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.
Mir-Ihara P; De Las Vecillas L; Heredia R; Fiandor A; González-Muñoz M; Zamarrón E; Prados C; Cabañas R
J Investig Allergol Clin Immunol; 2024 Jun; 34(3):211-213. PubMed ID: 37966860
[No Abstract] [Full Text] [Related]
12. An acneiform eruption associated with elexacaftor/tezacaftor/ivacaftor treatment.
Breneman A; Soliman YS; Gallitano SM
Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130408
[No Abstract] [Full Text] [Related]
13. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
[TBL] [Abstract][Full Text] [Related]
14. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
[TBL] [Abstract][Full Text] [Related]
15. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
Wei C; Liu Y; Jiang A; Wu B
Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
[No Abstract] [Full Text] [Related]
17. Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis.
Rotolo SM; Duehlmeyer S; Slack SM; Jacobs HR; Heckman B
J Cyst Fibros; 2020 Sep; 19(5):e39-e41. PubMed ID: 32471772
[TBL] [Abstract][Full Text] [Related]
18. Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.
Li D; Zhu Y; Donnelley M; Parsons D; Habgood MD; Schneider-Futschik EK
Biomed Pharmacother; 2024 Feb; 171():116155. PubMed ID: 38232663
[TBL] [Abstract][Full Text] [Related]
19. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
Dohna M; Voskrebenzev A; Klimeš F; Kaireit TF; Glandorf J; Pallenberg ST; Ringshausen FC; Hansen G; Renz DM; Wacker F; Dittrich AM; Vogel-Claussen J
Radiol Cardiothorac Imaging; 2024 Apr; 6(2):e230104. PubMed ID: 38573129
[TBL] [Abstract][Full Text] [Related]
20. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
Young D; Bartlett LE; Guimbellot J; Milinic T; Burdis N; Gill ER; Lease ED; Goss CH; Kapnadak SG; Ramos KJ
J Cyst Fibros; 2024 May; 23(3):545-548. PubMed ID: 37798159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
